Reach the investors backing rounds like this
Backed by South Park Commons · verified emails and LinkedIn on Datapile

Nasal GLP-1 startup LionBio raises $6M pre-seed - Dealroom
LionBio is developing nanoparticle-based GLP-1 treatments delivered through the nose, with its first candidate being a nasal formulation of semaglutide. The startup aims to expand into peptide treatments for neurological conditions and targets the olfactory epithelium for drug delivery to the brain. This pre-seed round will support its preclinical development and manufacturing scale-up.
Nasal GLP-1 startup LionBio raises $6M pre-seed Dealroom

| Nov 19, 2026 | Upwind | $400.0M | Series C | United States |
| Nov 19, 2026 | Tesorai | $5.3M | Seed | United States |
| Nov 19, 2026 | Modern Industrials | $6.0M | Seed | United States |
| Nov 19, 2026 | Rogo | $350.0M | — | United States |
You just read who funded LionBio. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.